The present invention provides a novel compound having FGFR inhibitory activity or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition containing the same,. Specifically, the present invention provides a compound represented by the following formula (I) or a pharmaceutically acceptable salt thereof: wherein n represents 0 to 2 A represents an arylene group or a heteroarylene group G represents a single bond, an oxygen atom or -CH2- E represents a nitrogen-containing non-aromatic heterocycle R1 represents an alkoxy group, an alkoxy alkoxy group or the like R2 represents a hydrogen atom, a halogen atom, a hydroxyl group, an alkyl group, a hydroxy alkyl group, a nitrogen-containing non-aromatic heterocyclic group or the like and R3 represents a hydrogen atom, an alkyl group, an alkoxy group or the like, with the proviso that when E represents an azetidine ring and R2 or R3 is present on a nitrogen atom on the azetidine ring, the R2 or R3 does not represent a hydrogen atom.本發明提供一種具有FGFR抑制活性之新化合物或其藥學上可接受的鹽,以及包含其之藥物組合物。確切地,本發明提供由以下式(I)代表之化合物或其藥學上可接受的鹽:其中n代表0至2;A代表伸芳基或雜伸芳基;G代表單鍵,氧原子或-CH2-;E代表一含氮非芳族雜環;R1代表一個烷氧基、烷氧基烷氧基或類似物;R2代表氫原子、鹵原子、羥基、烷基、羥基烷基、含氮非芳族雜環基團或類似物;並且R3代表氫原子、烷基、烷氧基或類似物,條件係當E代表氮雜環丁烷環並且R2或R3存在於該氮雜環丁烷環上的氮原子上時,該R2或R3不代表氫原子。
